Quoin Pharmaceuticals, Ltd.
QNRX evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $13.6M
- Lead Asset:
- qrx003 (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for QNRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QNRX
Quoin Pharmaceuticals (QNRX) is a late clinical-stage specialty pharmaceutical company developing QRX003 for Netherton Syndrome and other rare/orphan diseases, with a focus on commercial readiness and global regulatory approvals.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$13.6M
Cash Runway
—
Lead Asset
qrx003 (Phase 2/Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials for Quoin Pharmaceuticals, Ltd..
Quoin Pharmaceuticals (QNRX) is a late clinical-stage specialty pharmaceutical company developing QRX003 for Netherton Syndrome and other rare/orphan diseases, with a focus on commercial readiness and global regulatory approvals.
- Lead product QRX003 is in pivotal registrational clinical testing for Netherton Syndrome under an open FDA IND, with six U.S. and three UK clinical sites [sec · filed 2026-09-18].
- Cash and equivalents were $3.8M as of 2026-06-30, with net income of -$5.4M and shareholders' equity of $3.9M [sec].
- The company secured Orphan Drug Designations for QRX003 in the U.S. and Europe, and Fast Track Designation in the U.S. [news · published 2026-03-26].
- QRX003 is being tested in eight pediatric NS patients in a Compassionate Use program across Ireland, Austria, the Netherlands, and New Zealand [sec · filed 2026-09-18].
- Quoin closed a private placement financing of up to $104.5 million to support clinical and commercial activities [news · published 2026-03-26].
What works
- QRX003 has received Orphan Drug Designations in the U.S. and Europe, and Fast Track Designation in the U.S., which may expedite development and market access [news · published 2026-03-26].
- The company has established a global commercial infrastructure plan, including sales infrastructure in the U.S., Europe, and Japan, and distribution partners in multiple territories [sec · filed 2026-09-18].
- Positive long-term efficacy data with no reported safety concerns from ongoing clinical studies support the potential of QRX003 [news · published 2026-03-26].
What to weigh
- The company reported a net loss of -$5.4M for the period ending 2026-06-30, indicating ongoing operational cash burn [sec].
- Cash reserves of $3.8M as of 2026-06-30 are relatively limited for a company planning late-stage trials and commercialization [sec].
- QRX003 is still in clinical testing and has not yet received marketing approval in any territory, creating regulatory and commercial uncertainty [sec · filed 2026-09-18].
From the filings
Quoted directly from source documents.
QRX003 is entering pivotal registrational clinical testing for Netherton Syndrome under an open FDA IND.
“QRX003 is entering pivotal registrational clinical testing under an open IND application with the FDA.”
SEC filings · September 18, 2026
The company closed a private placement financing of up to $104.5 million.
“Closes Private Placement Financing of Up to $104.5 Million”
News · March 26, 2026
QRX003 is being tested in eight pediatric NS patients in a Compassionate Use program.
“QRX003 is currently being tested in eight pediatric NS patients in a Compassionate Use program in Ireland, Austria, the Netherlands and New Zealand”
SEC filings · September 18, 2026
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash of $3.8M as of 2026-06-30 may be insufficient to complete late-stage trials and commercialization without additional financing [sec].
- No approved product yet — QRX003 has not received marketing approval in any jurisdiction, creating regulatory and commercial risk [sec · filed 2026-09-18].
- Dependence on single lead asset — The company's pipeline is heavily reliant on QRX003, with limited diversification across other programs [sec · filed 2026-09-18].
What to watch
- Initiation of the first company-sponsored Phase 2/3 study for QRX003 in Peeling Skin Syndrome, expected in 2H 2026 [news · published 2026-08-14].
- Progress of the pediatric Compassionate Use program for QRX003 in Netherton Syndrome, with additional patients expected [sec · filed 2026-09-18].
- Regulatory decisions on marketing approval applications for QRX003 in the U.S., Europe, and Japan [sec · filed 2026-09-18].
- Financial sustainability and potential need for further capital raises given the net loss and cash position [sec].
Sources: News · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Quoin Pharmaceuticals, Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Quoin Pharmaceuticals, Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.04
Lead: Phase 2/Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$7.8M
| Holder | Shares | Value |
|---|---|---|
| ikarian capital, llc | 211,538 | $1.4M |
| dauntless investment group, llc | 196,592 | $1.3M |
| summittx capital, l.p. | 100,300 | $662K |
| velan capital investment management lp | 84,849 | $560K |
| woodline partners lp | 79,582 | $525K |
| millennium management llc | 76,247 | $503K |
| aberdeen group plc | 75,000 | $495K |
| soleus capital management, l.p. | 72,730 | $480K |
| centiva capital, lp | 60,000 | $396K |
| boothbay fund management, llc | 59,838 | $395K |
Showing top 10 of 21 institutional holders of Quoin Pharmaceuticals, Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 4.8%
- Days to cover
- 2.2
- Shares short
- 85,556
- Daily short volume (May 4, 2026)
- 41.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QNRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Quoin Pharmaceuticals, Ltd.?
Quoin Pharmaceuticals (QNRX) is a late clinical-stage specialty pharmaceutical company developing QRX003 for Netherton Syndrome and other rare/orphan diseases, with a focus on commercial readiness and global regulatory approvals.
What is Quoin Pharmaceuticals, Ltd.'s lead drug candidate?
Quoin Pharmaceuticals, Ltd.'s most advanced tracked candidate is qrx003 (Phase 2/Phase 3) for Netherton Syndrome.
Who is the CEO of Quoin Pharmaceuticals, Ltd.?
Dr. Michael Myers Ph.D. is the chief executive officer of Quoin Pharmaceuticals, Ltd. (QNRX).
Where is Quoin Pharmaceuticals, Ltd. headquartered?
Quoin Pharmaceuticals, Ltd. (QNRX) is headquartered in Ashburn, VA, United States.
What therapeutic areas does Quoin Pharmaceuticals, Ltd. focus on?
Quoin Pharmaceuticals, Ltd. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.